U.S. Markets close in 5 hrs 39 mins

GoodRx Holdings, Inc. (GDRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.99-0.16 (-0.40%)
As of 10:21AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close40.15
Open40.34
Bid39.66 x 800
Ask39.73 x 1200
Day's Range39.20 - 40.39
52 Week Range33.39 - 64.22
Volume203,358
Avg. Volume2,303,830
Market Cap15.681B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.33
  • These 3 Stocks Are Absurdly Overvalued Right Now
    Motley Fool

    These 3 Stocks Are Absurdly Overvalued Right Now

    One of the dangers of investing right now is that there are many high-priced stocks out there. GoodRx's business makes it easier for consumers to buy prescriptions at lower prices. GoodRx's lack of an edge is especially concerning given one of its competitors may end up being Amazon (NASDAQ: AMZN).

  • Motley Fool

    Are Ultra-High Drug Prices Sustainable?

    Goodrx (NASDAQ: GDRX) recently released its list of the 10 most expensive drugs on the market. Novartis' (NYSE: NVS) gene therapy Zolgensma remains at the top, but newcomers Eiger Pharmaceuticals (NASDAQ: EIGR) and Y-mAbs Therapeutics (NASDAQ: YMAB) took second and third place with Zokinvy and Danyelza, respectively. In this video from Motley Fool Live, recorded on March 15, Fool.com Contributors Brian Orelli and Keith Speights discuss the high-priced drugs and whether the prices are sustainable in the long run.

  • Motley Fool

    Can GoodRx Bounce Back From Its Pandemic Slowdown?

    The COVID-19 pandemic produced a growth slowdown at pharmaceutical drug discounter GoodRx Holdings (NASDAQ: GDRX). The increase in physical distancing also blunted the flu season, which further reduced the need for medications. In this video from Motley Fool Live, recorded on March 15, Fool.com Contributors Brian Orelli and Keith Speights discuss what outside factors could help GoodRx accelerate growth in the quarters to come.